Summary of Medicenna Therapeutics Update - December 10, 2025 Company Overview - **Company**: Medicenna Therapeutics (OTCPK:MDNA.F) - **Focus**: Clinical stage immunotherapy company developing next-generation superkines, specifically engineered cytokines to treat serious cancers [3][5] Key Industry Insights - **Clinical Study**: ABILITY-1 study evaluating MDNA-11, a next-generation IL-2 superagonist, both as a monotherapy and in combination with pembrolizumab (Keytruda) [2][10] - **Target Indications**: Advanced refractory solid tumors, including cutaneous melanoma, MSI-high tumors, and other difficult-to-treat cancers [10][12] Core Findings and Data Clinical Data Highlights - **Safety Profile**: MDNA-11 demonstrated a manageable safety profile with over 90% of treatment-related adverse events being grade one or two, typically resolving within 48 hours [13][14] - **Efficacy**: - Objective response rate (ORR) of approximately 38% in secondary immune checkpoint inhibitor-resistant cutaneous melanoma [17] - In patients treated immediately after progression on checkpoint inhibitors, ORR was 42% with a disease control rate (DCR) of 83% [17] - Notable individual cases included a patient with MSI-high pancreatic cancer in remission for over 21 months and a cutaneous melanoma patient with over seven months of remission [16][32] Mechanistic Insights - **Mechanism of Action**: MDNA-11 is designed to preferentially activate CD8 T cells and NK cells while minimizing toxic immune overreactions associated with conventional IL-2 therapies [5][6] - **Pharmacodynamics**: Robust expansion of effector CD8 T cells and stem-like CD8 T cells observed, supporting the intended mechanism of action [26] Survival Data - **Overall Survival**: Patients achieving disease control had a median overall survival of approximately 120 weeks compared to 29 weeks for those without disease control [23][24] Strategic Development Plans - **Next Steps**: Continue enrollment in phase two eligible expansion cohorts and expand sample sizes in tumor types showing clinical efficacy [27][66] - **NeoCyte Study**: Collaboration to evaluate MDNA-11 in a neoadjuvant therapy context for high-risk resectable melanoma [27] Expert Opinions - **KOL Insights**: Experts highlighted MDNA-11's potential as a best-in-class IL-2 variant, particularly in refractory settings and its promising safety profile compared to historical IL-2 therapies [36][40] - **Combination Strategies**: Interest in combining MDNA-11 with existing checkpoint inhibitors like nivolumab and ipilimumab for enhanced efficacy [38][47] Additional Considerations - **Market Positioning**: MDNA-11 is positioned to address significant unmet medical needs in refractory cancer populations, particularly in melanoma and MSI-high tumors [30][34] - **Future Directions**: Potential for MDNA-11 to replace traditional IL-2 therapies in various treatment settings, including earlier lines of therapy as data matures [48][55] This summary encapsulates the critical insights and data presented during the Medicenna Therapeutics update, focusing on the company's innovative approach to cancer treatment and the promising results from the ABILITY-1 study.

Company Presentation & KOL Webinar MDNA11 Clinical Data Update 10 December 2025 ESMO-IO Congress 2025 Disclaimer Certain statements in this presentation may constitute "forward-looking statements" under applicable securities laws. These forward-looking statements include, but are not limited to, information about possible or assumed future results of the Medicenna Therapeutics Corp's (the "Company" or "Medicenna") business, clinical trials, drug development, financial condition, results of operations, liqui ...